Search

Your search keyword '"Hennermann, Julia B"' showing total 423 results

Search Constraints

Start Over You searched for: Author "Hennermann, Julia B" Remove constraint Author: "Hennermann, Julia B"
423 results on '"Hennermann, Julia B"'

Search Results

2. Disease characteristics, effectiveness, and safety of vestronidase alfa for the treatment of patients with mucopolysaccharidosis VII in a novel, longitudinal, multicenter disease monitoring program

3. Monitoring and integrated care coordination of patients with alpha-mannosidosis: A global Delphi consensus study

4. Continued improvement in disease manifestations of acid sphingomyelinase deficiency for adults with up to 2 years of olipudase alfa treatment: open-label extension of the ASCEND trial

12. The PompeQoL questionnaire: Development and validation of a new measure for children and adolescents with Pompe disease.

15. Outcomes after newborn screening for propionic and methylmalonic acidemia and homocystinurias

16. Sphingolipidosen

17. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

22. Long-Term Outcome of Infantile Onset Pompe Disease Patients Treated with Enzyme Replacement Therapy - Data from a German-Austrian Cohort

24. Treatment Outcomes for Maple Syrup Urine Disease Detected by Newborn Screening.

28. Sulfite oxidase deficiency causes persulfidation loss and H2S release

30. Neurological outcome in long‐chain hydroxy fatty acid oxidation disorders

35. Clinical outcomes and survival of individuals with methylmalonic acidemia, propionic acidemia, classic homocystinuria, and remethylation disorders identified through newborn screening

36. Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samples

40. A Delphi consensus approach to monitoring and integrated care coordination of patients with alpha-mannosidosis

42. Outcome of Patients with Classical Infantile Pompe Disease Receiving Enzyme Replacement Therapy in Germany

43. Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis:A phase 2, open label, multicenter study

47. Isovaleric aciduria identified by newborn screening: Strategies to predict disease severity and stratify treatment.

48. Long‐term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha‐mannosidosis: A phase 2, open label, multicenter study

Catalog

Books, media, physical & digital resources